|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar
|
|
2
|
Langer CJ, Besse B, Gualberto A, Brambilla
E and Soria JC: The evolving role of histology in the management of
advanced non-small-cell lung cancer. J Clin Oncol. 28:5311–5320.
2010. View Article : Google Scholar
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
4
|
Blaustein JD: Steroid hormone receptors:
Long- and short-term integrators of the internal milieu and the
external environment. Horm Metab Res. 44:563–568. 2012. View Article : Google Scholar
|
|
5
|
Nair S and Sachdeva G: Estrogen matters in
metastasis. Steroids. 138:108–116. 2018. View Article : Google Scholar
|
|
6
|
Fan S, Liao Y, Liu C, Huang Q, Liang H, Ai
B, Fu S and Zhou S: Estrogen promotes tumor metastasis via estrogen
receptor beta-mediated regulation of matrix-metalloproteinase-2 in
non-small cell lung cancer. Oncotarget. 8:56443–56459. 2017.
|
|
7
|
Chlebowski RT, Schwartz AG, Wakelee H,
Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW,
Wactawski-Wende J, Gass M, et al Women's Health Initiative
Investigators, : Oestrogen plus progestin and lung cancer in
postmenopausal women (Women's Health Initiative trial): A post-hoc
analysis of a randomised controlled trial. Lancet. 374:1243–1251.
2009. View Article : Google Scholar :
|
|
8
|
Garon EB, Siegfried JM, Stabile LP, Young
PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh
RJ, et al: Randomized phase II study of fulvestrant and erlotinib
compared with erlotinib alone in patients with advanced or
metastatic non-small cell lung cancer. Lung Cancer. 123:91–98.
2018. View Article : Google Scholar :
|
|
9
|
Brown M and O'Reilly S: Innate immunity
and Toll-like receptor signaling in the pathogenesis of
scleroderma: Advances and opportunities for therapy. Curr Opin
Rheumatol. 30:600–605. 2018. View Article : Google Scholar
|
|
10
|
Akira S, Uematsu S and Takeuchi O:
Pathogen recognition and innate immunity. Cell. 124:783–801. 2006.
View Article : Google Scholar
|
|
11
|
Janeway CA Jr and Medzhitov R:
Introduction: The role of innate immunity in the adaptive immune
response. Semin Immunol. 10:349–350. 1998. View Article : Google Scholar
|
|
12
|
Bhattacharya D and Yusuf N: Expression of
toll-like receptors on breast tumors: Taking a toll on tumor
microenvironment. Int J Breast Cancer. 2012:7165642012. View Article : Google Scholar
|
|
13
|
Anthoney N, Foldi I and Hidalgo A: Toll
and Toll-like receptor signalling in development. Development.
145:1452018. View Article : Google Scholar
|
|
14
|
Chow SC, Gowing SD, Cools-Lartigue JJ,
Chen CB, Berube J, Yoon HW, Chan CH, Rousseau MC, Bourdeau F,
Giannias B, et al: Gram negative bacteria increase non-small cell
lung cancer metastasis via Toll-like receptor 4 activation and
mitogen-activated protein kinase phosphorylation. Int J Cancer.
136:1341–1350. 2015. View Article : Google Scholar
|
|
15
|
Li D, Jin Y, Sun Y, Lei J and Liu C:
Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell
growth and inflammatory cytokine secretion in vitro and
in vivo. Int J Oncol. 45:813–821. 2014. View Article : Google Scholar
|
|
16
|
Harmey JH, Bucana CD, Lu W, Byrne AM,
McDonnell S, Lynch C, Bouchier-Hayes D and Dong Z:
Lipopolysaccharide-induced metastatic growth is associated with
increased angiogenesis, vascular permeability and tumor cell
invasion. Int J Cancer. 101:415–422. 2002. View Article : Google Scholar
|
|
17
|
Lv W, Chen N, Lin Y, Ma H, Ruan Y, Li Z,
Li X, Pan X and Tian X: Macrophage migration inhibitory factor
promotes breast cancer metastasis via activation of HMGB1/TLR4/NF
kappa B axis. Cancer Lett. 375:245–255. 2016. View Article : Google Scholar
|
|
18
|
Rusch VW, Chansky K, Kindler HL, Nowak AK,
Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC,
Nakano T, et al IASLC Staging Prognostic Factors Committee,
advisory boards, participating institutions, : The IASLC
Mesothelioma Staging Project: Proposals for the M Descriptors and
for Revision of the TNM Stage Groupings in the Forthcoming (Eighth)
Edition of the TNM Classification for Mesothelioma. J Thorac Oncol.
11:2112–2119. 2016. View Article : Google Scholar
|
|
19
|
Tang H, Liao Y, Xu L, Zhang C, Liu Z, Deng
Y, Jiang Z, Fu S, Chen Z and Zhou S: Estrogen and insulin-like
growth factor 1 synergistically promote the development of lung
adenocarcinoma in mice. Int J Cancer. 133:2473–2482. 2013.
View Article : Google Scholar
|
|
20
|
Huang Q, Zhang Z, Liao Y, Liu C, Fan S,
Wei X, Ai B and Xiong J: 17β-estradiol upregulates IL6 expression
through the ERβ pathway to promote lung adenocarcinoma progression.
J Exp Clin Cancer Res. 37:1332018. View Article : Google Scholar :
|
|
21
|
Tang H, Liao Y, Chen G, Xu L, Zhang C, Ju
S and Zhou S: Estrogen upregulates the IGF-1 signaling pathway in
lung cancer through estrogen receptor-β. Med Oncol. 29:2640–2648.
2012. View Article : Google Scholar
|
|
22
|
Liu C, Liao Y, Fan S, Tang H, Jiang Z,
Zhou B, Xiong J, Zhou S, Zou M and Wang J: G protein-coupled
estrogen receptor (GPER) mediates NSCLC progression induced by
17β-estradiol (E2) and selective agonist G1. Med Oncol. 32:1042015.
View Article : Google Scholar
|
|
23
|
Hernandez H, Medina-Ortiz WE, Luan T,
Clark AF and McDowell CM: Crosstalk between transforming growth
factor beta-2 and Toll-like receptor 4 in the trabecular meshwork.
Invest Ophthalmol Vis Sci. 58:1811–1823. 2017. View Article : Google Scholar :
|
|
24
|
Shaaban AA, El-Kashef DH, Hamed MF and
El-Agamy DS: Protective effect of pristimerin against LPS-induced
acute lung injury in mice. Int Immunopharmacol. 59:31–39. 2018.
View Article : Google Scholar
|
|
25
|
Vinci M, Box C and Eccles SA:
Three-dimensional (3D) tumor spheroid invasion assay. J Vis Exp.
99:e526862015.
|
|
26
|
Del Pozo JL: Primers on molecular
pathways: Lipopolysaccharide signaling - potential role in
pancreatitis and pancreatic cancer. Pancreatology. 10:114–118.
2010. View Article : Google Scholar
|
|
27
|
Siegfried JM and Stabile LP: Estrongenic
steroid hormones in lung cancer. Semin Oncol. 41:5–16. 2014.
View Article : Google Scholar
|
|
28
|
Matsunaga N, Tsuchimori N, Matsumoto T and
Ii M: TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like
receptor (TLR) 4 signaling, binds selectively to TLR4 and
interferes with interactions between TLR4 and its adaptor
molecules. Mol Pharmacol. 79:34–41. 2011. View Article : Google Scholar
|
|
29
|
Thomas C and Gustafsson JA: The different
roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer.
11:597–608. 2011. View Article : Google Scholar
|
|
30
|
Weaver AM: Invadopodia: Specialized cell
structures for cancer invasion. Clin Exp Metastasis. 23:97–105.
2006. View Article : Google Scholar
|
|
31
|
Saykali BA and El-Sibai M: Invadopodia,
regulation, and assembly in cancer cell invasion. Cell Commun
Adhes. 21:207–212. 2014. View Article : Google Scholar
|
|
32
|
Goertzen CG, Dragan M, Turley E, Babwah AV
and Bhattacharya M: KISS1R signaling promotes invadopodia formation
in human breast cancer cell via β-arrestin2/ERK. Cell Signal.
28:165–176. 2016. View Article : Google Scholar
|
|
33
|
Kovats S: Estrogen receptors regulate
innate immune cells and signaling pathways. Cell Immunol.
294:63–69. 2015. View Article : Google Scholar :
|
|
34
|
Mai CW, Kang YB and Pichika MR: Should a
Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to
treat cancer? TLR-4: Its expression and effects in the ten most
common cancers. Onco Targets Ther. 6:1573–1587. 2013.
|
|
35
|
Rich AM, Hussaini HM, Parachuru VP and
Seymour GJ: Toll-like receptors and cancer, particularly oral
squamous cell carcinoma. Front Immunol. 5:4642014. View Article : Google Scholar :
|
|
36
|
Chiang AC and Massagué J: Molecular basis
of metastasis. N Engl J Med. 359:2814–2823. 2008. View Article : Google Scholar :
|
|
37
|
Alaseem A, Alhazzani K, Dondapati P,
Alobid S, Bishayee A and Rathinavelu A: Matrix Metalloproteinases:
A challenging paradigm of cancer management. Semin Cancer Biol.
56:100–115. 2019. View Article : Google Scholar
|
|
38
|
Brown GT and Murray GI: Current
mechanistic insights into the roles of matrix metalloproteinases in
tumour invasion and metastasis. J Pathol. 237:273–281. 2015.
View Article : Google Scholar
|
|
39
|
Prossnitz ER and Barton M: The
G-protein-coupled estrogen receptor GPER in health and disease. Nat
Rev Endocrinol. 7:715–726. 2011. View Article : Google Scholar :
|
